多西紫杉醇联合替吉奥治疗蒽环类耐药晚期乳腺癌的疗效观察  

Docetaxel combined with S-1 for anthracycline-resistant advanced breast cancer

作　　者：宋子琰[1] 郑义同[1] 卞宝祥[1] 

机构地区：[1]连云港市第一人民医院肿瘤内科,江苏连云港222000

出　　处：《临床肿瘤学杂志》2012年第2期150-152,共3页Chinese Clinical Oncology

摘　　要：目的观察多西紫杉醇联合替吉奥治疗蒽环类耐药晚期乳腺癌的疗效和不良反应。方法 21例蒽环类耐药晚期乳腺癌患者采用多西紫杉醇(75mg/m2静滴d1)联合替吉奥(80mg/m2/天,分2次口服,dl～d14)治疗,3周为1周期,2周期后按WHO标准评价疗效及不良反应。结果 21例患者均可评价疗效和不良反应,其中获CR 3例,PR 9例,SD 5例,PD4例,有效率为57.2%,临床获益率为81.0%。中位疾病进展时间为9.5个月,1年生存率为81.0%。主要不良反应为血液学毒性和消化道反应,以1、2级为主,均可耐受。结论多西紫杉醇联合替吉奥治疗蒽环类耐药晚期乳腺癌疗效肯定,不良反应较小,耐受性好,值得临床进一步研究。Objective To evaluate the efficacy and toxicity of docetaxel combined with S-1 for anthracycline-resistant advanced breast cancer. Methods Twenty-one patients with advanced breast cancer were treated with docetaxel （75mg/m^2 iv d1 ） and S-1 （80mg/m^2, oral administration, d1-d14 ）. Three weeks was a cycle. The efficacy and toxicity were evaluated by WHO standards after 2-cycle treatment. Results The efficacy and toxicity could be evaluated in the 21 patients with 3 of CR ,9 of PR ,5 of SD and 4 of PD. The response rate was 57.2% and clinical benefit rate was 81.0%. The median time to progress was 9.5 months and 1-year survival rate was 81.0%. The most common toxicities were hematological and digestive toxic reactions, mainly 1-2 degree, and could be well- tolerated. Conclusion The efficacy of docetaxel combined with S-1 for anthracycline-resistant advanced breast cancer is significant with well-tolerated toxicity, and worth further study.

关 键 词：多西紫杉醇 替吉奥 晚期乳腺癌 蒽环类药物 

分 类 号：R737.9[医药卫生—肿瘤]